Hill-Rom Holdings downgraded by B of A Securities with a new price target
$HRC
Medical/Dental Instruments
Health Care
B of A Securities downgraded Hill-Rom Holdings from Buy to Neutral and set a new price target of $130.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/20/2021 | $148.00 → $156.00 | Overweight → Equal-Weight | Morgan Stanley |
| 9/8/2021 | Overweight → Sector Weight | Keybanc | |
| 9/3/2021 | $150.00 → $156.00 | Outperform → Neutral | Baird |
| 8/10/2021 | $130.00 | Buy → Neutral | B of A Securities |
| 8/10/2021 | Buy → Neutral | BofA Securities | |
| 8/2/2021 | $131.00 → $145.00 | Overweight | Keybanc |
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400: Alcoa Corp. (NYSE:AA) will replace Hill-Rom Holdings Inc. (NYSE:HRC) in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 20. S&P 500 constituent Baxter International Inc. (NYSE:BAX) is acquiring Hill-Rom in a deal that was completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector December 20, 2021 S&P MidCap 400 Addition Alcoa AA Materials S&P MidCap 400 Deletion Hill-Rom Holdings HRC Health Care For more
CHICAGO, Dec. 2, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced that its shareholders have voted to approve the previously announced pending acquisition by Baxter International Inc. (NYCE: BAX) at a special meeting. Hillrom shareholders voted overwhelmingly in favor of the transaction. Under the terms of the merger agreement, Hillrom shareholders will receive $156.00 per share in cash for every share of Hillrom stock they own immediately prior to the effective time of the merger. "The strong support of our investors over the years and in today's shareholder vote is an
CHICAGO, Nov. 5, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced financial results for its fiscal fourth quarter and full-year ended September 30, 2021. For the fiscal fourth quarter, Hillrom reported GAAP earnings of $0.80 per diluted share, an increase of 27 percent compared to $0.63 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.67 per diluted share increased 43 percent and exceeded the company's previously-issued guidance range of $1.44 to $1.48 per diluted share. Adjustments to reported earnings are detail
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
4 - Hill-Rom Holdings, Inc. (0000047518) (Issuer)
15-12B - Hill-Rom Holdings, Inc. (0000047518) (Filer)
10-K/A - Hill-Rom Holdings, Inc. (0000047518) (Filer)
S-8 POS - Hill-Rom Holdings, Inc. (0000047518) (Filer)
Morgan Stanley downgraded Hill-Rom Holdings from Overweight to Equal-Weight and set a new price target of $156.00 from $148.00 previously
Keybanc downgraded Hill-Rom Holdings from Overweight to Sector Weight
Baird downgraded Hill-Rom Holdings from Outperform to Neutral and set a new price target of $156.00 from $150.00 previously
SC 13G/A - Hill-Rom Holdings, Inc. (0000047518) (Subject)
SC 13G/A - Hill-Rom Holdings, Inc. (0000047518) (Subject)
SC 13G/A - Hill-Rom Holdings, Inc. (0000047518) (Subject)
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20211213-1447634/1447634_4hrc.pdf
Hillrom (NYSE:HRC) today announced that its shareholders have voted to approve the previously announced pending acquisition by Baxter International Inc. (NYCE: BAX) at a special meeting. Hillrom shareholders voted overwhelmingly in favor of the transaction. Under the terms of the merger agreement, Hillrom shareholders will receive $156.00 per share in cash for every share of Hillrom stock they own immediately prior to the effective time of the merger. "The strong support of our investors over the years and in today's shareholder vote is an important validation of our vision of Advancing Connected Care™, and we are proud of the significant shareholder value creation that has occurred due t
CHICAGO, Nov. 5, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) today announced financial results for its fiscal fourth quarter and full-year ended September 30, 2021. For the fiscal fourth quarter, Hillrom reported GAAP earnings of $0.80 per diluted share, an increase of 27 percent compared to $0.63 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.67 per diluted share increased 43 percent and exceeded the company's previously-issued guidance range of $1.44 to $1.48 per diluted share. Adjustments to reported earnings are detail
CHICAGO, Nov. 2, 2021 /PRNewswire/ -- Hillrom (NYSE:HRC) announced today that its board of directors declared a quarterly dividend of $0.24 per share payable on December 31, 2021, to shareholders of record as of the close of business on December 15, 2021. The indicated annual dividend rate is $0.96 per share. About HillromHillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the world, our innovations touch over 7 million patients each day. They help
BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth equity portfolio: On August 6, HillRom (NYSE:HRC) completed the acquisition of SV's portfolio company Bardy Diagnostics ("BDx"). In 2016, SV partnered with founder Dr. Gust Bardy to support the commercial launch of the Carnation Ambulatory Monitor, a best-in-class ambulatory cardiac monitor. The CAM offers both superior patient convenience and improved data capture. During the course of SV's partnership with BDx, the company built an increasingly sophisticated services capability and grew revenue ten-fold. SV wishes t
SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced today the appointment of Amy Salzhauer and Greg Miller to the company's Board of Directors. Ms. Salzhauer currently serves as a Founder and Managing Partner at Good Growth Capital (GGC), an early-stage venture capital firm known for its exceptional expertise in finding, cultivating, and assessing complex science and technology start-ups based in Charleston, SC and Boston, MA. Mr. Miller recently retired as Executive Vice President and Chief Information Officer of Genuine Parts C
WAYNE, Pa.--(BUSINESS WIRE)--Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced that Stacy Enxing Seng has joined the board of directors effective immediately. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture. She currently serves as a venture partner for Lightstone Ventures and since 2013 has a